FCGR2B and neoplasm: The significant difference in CD32B/CD19 expression between histological grades also supports the hypothesis that higher CD32B expression in lower-grade tumors may suppress immune activation in the early stages of tumor development, while more aggressive tumors show a reduced difference in expression.